Q2 2024 Earnings

Revenue

$8M+32.1% YoY

Gross Profit

$5M63.5% margin

Operating Income

-$5M-60.3% margin

Net Income

-$4M-56.1% margin

EPS (Diluted)

$-0.16

QoQ Revenue Growth

+2.9%

Operating Cash Flow

-$3M

Free Cash Flow

-$3M

Stock-Based Comp.

$2M

Total Assets

$53M

Total Liabilities

$20M

Stockholders' Equity

$32M

Cash & Equivalents

$33M

Metric	Current	Year Ago	Change
Revenue	$8M	$6M	+32.1%
Gross Profit	$5M	$3M	+59.6%
Operating Income	-$5M	-$7M	+33.5%
Net Income	-$4M	-$7M	+37.5%

Biologics And Drug Delivery

$4M55%

Biologics And Drug Delivery - Disposable Products

$2M21%

Capital Equipment And Software

$945,00012%

Capital Equipment And Software - Systems and Software Products

$687,0009%

Capital Equipment And Software - Services

$258,0003%